This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
We are seeking a law student for a paid IP/Trademark internship ($25/hr) from May 2025 to August 2025 (dates are flexible, minimum 10 weeks is required). Applications will be accepted through February 28, 2025. The post EMP&A Accepting Summer 2025 Intern Applications appeared first on Erik M Pelton & Associates, PLLC.
This Article analyzes over 89,000 patentslitigated over a twenty-year period to determine how the number of office actions to allowance during prosecution impacts rates of invalidity during subsequent litigation. Originally published in volume 38, issue 1 of the Harvard Journal of Law & Technology, February 2025.
Etanercept Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are counted more than once. Within each litigation a claim is counted only once.
On March 24, 2025, the United States Patent and Tradmark Office (USPTO) issued a new Memorandum providing guidance on discretionary denials (or Fintiv denials) for inter partes review (IPR) challenges based on co-pending patentlitigation.
Rituximab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are counted more than once. Within each litigation a claim is counted only once.
In less than a month, the United States Patent and Trademark Office (USPTO) has dramatically reformed its policies and procedures for exercising its discretion to deny institution of AIA post-grant proceedings. By: Hudnell Law Group
Insulin Glargine Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are counted more than once. By: Venable LLP
On February 28, 2025, the United States Patent and Trademark Office (USPTO) rescinded a memorandum issued in June 2022 by former Director Katherine Vidal (the Vidal Memorandum) that provided guidance on discretionary denials at the Patent Trial and Appeal Board (PTAB or the Board). Then, on March 24, 2025, the.
Patent and Trade Office (PTO) on February 28, 2025, rescinded former PTO Director Kathi Vidal's June 21, 2022, memorandum (Memorandum) addressing discretionary denial of inter partes review (IPR) of patents that are subject to parallel district court litigation.
The first is the Summer Course on European Intellectual Property Law , which will take place in person in Trier (Germany) between 30 June and 4 July 2025. The second is the Summer Course on EU Digital and Information Technology Law , which will take place online between 15 and 16 September 2025.
On January 8, 2025, the Delhi High Court, presided over by Hon’ble Justice Amit Bansal, delivered a significant ruling in the case of Syngenta Limited and Anr. This case pertains to patent infringement concerning two process patents related to the fungicide Azoxystrobin. Image generated by DALL E and edited by Canva.
Etanercept Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are counted more than once. Within each litigation a claim is counted only once.
On February 10, 2025, the Federal Circuit issued a precedential decision in Kroy IP Holdings, LLC v. where the Court held that a a prior final written decision of the [PTAB] of unpatentability on separate patent claims. Groupon, Inc.,
This week on IPWatchdog Unleashed we present my fireside chat with Judge John Holcomb of the United States Federal District Court for the Central District of California, which took place March 4, 2025, at IPWatchdog LIVE. Federal District Court for the Central District of California.
Marcel Pemsel analysed two recent decisions from the General Court and the German Patent Court concerning applications for invalidity of an (almost) identical EU trade mark, Sophienwald. The survey closes on 1 April 2025. The BoA decided that the sign MAGIC PUSSY would not fall under the Article 7(1)(f) EUTMR.
In the European IP system, and thus also in the European patent system, the concept of injunction is central. This also applies to the Unified Patent Court (UPC); here, there are even two ways to obtain an injunction, one with a normal regular action on the merits and one by means of a preliminary injunction.
Rituximab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are counted more than once. Within each litigation a claim is counted only once.
Pegfilgrastim Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are counted more than once. Within each litigation a claim is counted only once.
Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are counted more than once. Within each litigation a claim is counted only once.
She shared several pertinent points on issues concerning expert evidence in IP litigations and what she thinks is the best way forward for the Indian Courts vis a vis engaging experts in IP matters. Malobika Sen (MS) : Could you elaborate on the role of expert evidence in IP litigation? Prabha Sridevan Justice (Retd.)
Adalimumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are counted more than once. Within each litigation a claim is counted only once.
Welcome to the Intellectual Property Litigation Newsletter, our review of decisions and trends in the intellectual property arena. In this edition, we learn that the Federal Circuit always says never, patent publications can come after the priority date, and warnings arent always a safe harbor. By: Alston & Bird
Adalimumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are counted more than once. Within each litigation a claim is counted only once.
A stroll along the Amsterdam canals is a must The Katfriends at Kisaco Research are back with a 3-day conference aimed at patent-focussed IPKat readers. The P harma & Biotech PatentLitigation Summit will take place in Amsterdam on 21 and 22 January 2025, with the UPC Litigation Forum taking place on 20 January.
Case Summaries Vst Industries Limited vs Asd Tobacco Private Limited & Anr on 6 March, 2025 (Delhi High Court) The petitioner, filed the petition to remove the respondents registration for the mark CHUMS from the Trade Mark Register. vs Clubramada Hotels And Resorts Private Limited on 9 March, 2025 (Delhi High Court) Image from here.
Litigation funding resulting in more heated disputes, artificial intelligence tools becoming a fact of life for patent attorneys and increased use of patent reexaminations are among the trends attorneys will be keeping tabs on in the coming year.
14, 2025) (Lourie, J.). This latest ruling stands in contrast to the court's January 2025 decisions upholding preliminary injunctions against Samsung Bioepis and Formycon, effectively blocking their biosimilar launches. All three cases are part of consolidated multi-district litigation in the Northern District of West Virginia.
The case law surrounding patent apportionment has evolved significantly, with the Federal Circuit increasingly scrutinizing patentlitigants reliance on comparable licenses as a means for calculating a reasonable royalty. With EcoFactor, Inc. By: Baker Botts L.L.P.
On Friday, March 14, 2025, Delaware's own Judge Andrews provided important guidance on key patent issues, relevant to pharmaceutical and technology companies alike: (1) the decisive impact of local patent rules on summary judgment and (2) mitigating the risks of an IPXL challenge by careful claim drafting. By: Venable LLP
On February 28, 2025, the acting director of the US Patent & Trademark Office (PTO) announced that the agency will revert to previous guidelines for discretionary denials of petitions for post-grant proceedings where there is ongoing district court litigation. By: McDermott Will & Emery
Standard Essential Patents are on the Rise, as is Litigation - Standard-essential patents (SEPs) are on the rise as connectivity, a present-day necessity, relies on standards subject to SEPs. The economic impact of these “connected” devices is estimated to be approximately $10 trillion per year by 2025.
On Friday, February 28, 2025, the United States Patent and Trademark Office (USPTO) announced the withdrawal of the June 2022 memorandum titled Interim Procedure for Discretionary Denials in AIA Post-Grant Proceedings with Parallel District Court Litigation, which had been issued by former USPTO Director Kathi Vidal.
ANI-OpenAI litigation. Call for Suggestions on the Draft Guidelines for Processing Patent Applications of AYUSH Systems and Related Inventions (February 28) IndiaAI, an initiative of the MeitY has invited comments on a report titled AI Governance and Guidelines Development. on 14 February, 2025, (Delhi HC) Manash Lifestyle Pvt.
(Retd) Sukesh Behl ) in three cases concerning allegations of infringement of a Standard Essential Patent relating to Philips DVD player technology. Filed in 2012, the decision comes after 13 years with the litigation having outlived not only the suit patent, and the DVD industry, but also the institution that declared it essential !!
The case highlights some interesting aspects of pharma IP strategy, particularly as related to manufacturing IP and whether this is best protected with patents or trade secrets. However, manufacturing patents bring with them a number of risks and potential pitfalls.
ANI-OpenAI litigation. Call for Suggestions on the Draft Guidelines for Processing Patent Applications of AYUSH Systems and Related Inventions (February 28) IndiaAI, an initiative of the MeitY has invited comments on a report titled AI Governance and Guidelines Development. on 14 February, 2025, (Delhi HC) Manash Lifestyle Pvt.
On March 17, 2025, a bipartisan group of senators introduced two bills intended to decrease the cost of prescription drugs. Passage of one or both may alter patent portfolio management and patentlitigation strategy for pharmaceuticals and biologics. and Dick Durbin (D-Ill.).
Join Wolf Greenfield for a mid-year review of litigation and PTAB trends at 12:00pm ET or 9:00pm ET. This webinar will cover: 2024/2025patentlitigation trends: ITC domestic industry, double patenting, forum shopping, legislative proposals, and more. Will the 2025 PTAB look like the 2024 PTAB? Legislation?
Join Wolf Greenfield for a mid-year review of litigation and PTAB trends at 12:00pm ET or 9:00pm ET. This webinar will cover: 2024/2025patentlitigation trends: ITC domestic industry, double patenting, forum shopping, legislative proposals, and more. Will the 2025 PTAB look like the 2024 PTAB? Legislation?
Government Urged to Invoke Section 100, Patents Act for Rare Disease Medicine MP Haris Beeran has written to the Minister of Health and Family Welfare urging the government to invoke Section 100 of the Patents Act, seeking local production of the rare disease medicine Risdiplam. Who Notices When Patents Are Revoked/Invalidated?
The Paris Local Division of the Unified Patent Court (UPC) first substantive decision on patent validity in DexCom v Abbott ( UPC_CFI_230/2023 ), provides some interesting commentary on how much the description should be taken into account when interpreting the claims. DexCom alleged infringement by Abbott's FreeStyle Libre 2 products.
Dr Chijioke Okorie , who joined the IPKat at the start of 2019 as our first Africa Correspondent , has been promoted to Associate Professor at the University of Pretoria, effective 1 January 2025. Readers will already know that this year's CIPIL Annual Lecture has been scheduled for 18 March 2025 to be delivered by Robert P.
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content